INDEPENDENT MEDIA NETWORK. TECH. IDEAS. PEOPLE.
A BRIGHTER TOMORROW — TODAY.
🌐|||
MEDICINE

Mapping Glioma Margins: FDA Approves Telix's Pixclara PET Imaging Agent

Overcoming MRI edema limitations, 18F-FET selectively illuminates malignant glioma tissue with unprecedented contrast.

Alex Carter
Alex Carter
Sep 15, 2026•3 min read
Mapping Glioma Margins: FDA Approves Telix's Pixclara PET Imaging Agent

⚡️ LAT1 Amino Acid Transport & High-Contrast PET

The active molecule in Pixclara (18F-FET) is a synthetic tyrosine analog labeled with fluorine-18. Malignant glioma cells dramatically overexpress LAT1 / LAT2 amino acid transporters to satisfy voracious protein synthesis demands.

Unlike standard FDG glucose tracers, healthy cerebral cortex neurons minimally absorb fluoroethyltyrosine. This creates an ultra-sharp tumor margin with a 4.8:1 contrast ratio, empowering surgeons to guide laser resections with sub-0.8 mm precision.

📊 Clinical & Diagnostic Parameters of Pixclara

: 94.2% (vs 68% for MRI)

: Sub-millimeter (0.8 mm)

: 109.8 mins (Fluorine-18)

: Full US FDA Approval

🩺 Molecular Neurosurgical Navigation Protocol

Точность резекции
Субмиллиметровая
Молекулярная мишень
Транспортер LAT1 / LAT2
Статус регулятора
Полное одобрение FDA